Stay updated on Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedAdded glossary term 'Inflammatory breast carcinoma' and a new Resources entry for Genetic and Rare Diseases Information Center. Updated the revision note from v3.4.3 to v3.5.0.SummaryDifference0.2%

- Check25 days agoChange DetectedRevision: v3.4.3 is now displayed on the page, replacing v3.4.2.SummaryDifference0.1%

- Check54 days agoChange DetectedAdministrative site updates: a new revision entry (v3.4.2) and removal of an older funding notice; these changes do not affect the study details or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check61 days agoChange DetectedAdded a government-funding notice banner indicating the NIH Clinical Center is open and where to check status updates (opm.gov). Updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check68 days agoChange DetectedAdded results posting information and new outcomes for the study, including DFS definitions and adverse-event metrics with follow-up times, and linked a PDF of the Study Protocol and SAP. The page's study documents section was updated and some prior analysis details were removed.SummaryDifference3%

- Check82 days agoChange DetectedRevision: v3.3.4 was added and the previous v3.3.3 revision was removed, representing a minor technical update with no changes to study content or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial page.